* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:ABOT vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories (Pakistan) Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories (Pakistan)'s Days Payable falls into.
Abbott Laboratories (Pakistan) Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) (KAR:ABOT) has a Days Payable of 53.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott Laboratories (Pakistan) and its competitors. This is 54% above median its historical median of 34.52. Over the past decade, Abbott Laboratories (Pakistan)'s Days Payable has ranged from 24.61 to 67.16. According to the industry distribution chart, Abbott Laboratories (Pakistan) ranks #745 out of 922 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Abbott Laboratories (Pakistan)'s Days Payable too high?
Abbott Laboratories (Pakistan)'s current Days Payable of 53.24 is 54% above median its 10-year median of 34.52. Over the past 10 years, this metric has ranged from a low of 24.61 to a high of 67.16. The Drug Manufacturers industry median Days Payable is 90.84. Abbott Laboratories (Pakistan)'s value of 53.24 is 41.4% below this industry median. Based on the distribution chart, Abbott Laboratories (Pakistan) ranks #745 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott Laboratories (Pakistan) ranks #745 out of 922 companies for Days Payable. This places Abbott Laboratories (Pakistan) in the lower half of its industry. The industry median Days Payable is 90.84. Abbott Laboratories (Pakistan)'s value of 53.24 is 41.4% below this benchmark. Historically, Abbott Laboratories (Pakistan)'s own Days Payable has ranged from 24.61 to 67.16 over the past decade. While the company's 10-year median is 34.52 vs. the industry median of 90.84, Abbott Laboratories (Pakistan) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories (Pakistan)'s current Days Payable of 53.24 is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott Laboratories (Pakistan) and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories (Pakistan)'s current Days Payable is 53.24, which is 54% above median its own 10-year median of 34.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,004.14, compared to a current price of ₨1,019.35 — trading 1.5% above its estimated fair value. The current Days Payable is 53.24, which is 54% above median its 10-year median of 34.52 and 41.4% below the Drug Manufacturers industry median of 90.84. Abbott Laboratories (Pakistan)'s overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current Days Payable is 53.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be overvalued.
The current stock price of ₨1,019.35 is trading 1.5% above its estimated GF Value™ of ₨1,004.14.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
Days Payable: 53.24 (54% above median its 10-year median of 34.52)
GF Value™: ₨1,004.14 vs. price of ₨1,019.35 (1.5% above fair value)
Industry Position: 41.4% below the Drug Manufacturers median (#745 of 922)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
79GF Score
Get the complete analysis for KAR:ABOT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
